Regulators approved the injection, which significantly cuts administration time versus the intravenous formulation, based on a Phase III comparison of the two.

This is the first and only subcutaneous immune checkpoint inhibitor in Europe that a health care provider can administer in ...

During a live event, Moshe C. Ornstein, MD, MA, considered the trial design and outcomes of 2 trials of combination regimens ...

The company reported positive results from a trial of the heart drug that the company is counting on for much of its growth.

Libtayo plus chemotherapy is potentially more cost-effective than Keytruda plus chemotherapy for advanced NSCLC, offering lower costs and higher QALYs. The study's model, based on clinical trial data, ...

Jazz Pharmaceuticals and Zymeworks announced positive topline phase 3 results for Ziihera in HER2-positive GEA. Click here to ...

Ongoing research in renal cell carcinoma (RCC) suggests that hypoxia-inducible factor 2-alpha (HIF-2α) inhibitors are poised ...

Keytruda showed a significant survival benefit over Tecentriq and Opdivo in older adults with metastatic NSCLC, with a 33% ...

Merck announced the $9.2 billion deal with Cidara on Friday, sending Cidara's stock (CDTX) soaring 106% in recent morning trading, enough to make it the biggest gainer on the major U.S. exchanges. The ...

Merck will acquire Cidara Therapeutics in a nearly $9.2 billion deal, gaining access to an experimental flu drug in its ...

Merck will acquire Cidara Therapeutics for $9.2B to expand its respiratory portfolio, driven by demand for CD388 as ...

Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in ...